Gene Therapy for Myocardial Infarction: A Real Medicine in the Next Millenium?
replication of dead myocytes by genetically modified cardiac myocytes, and
prevention of myocardial infarction by NFкB decoy ODN. The use of genetically modified cells for the delivery of recombinant molecules has emerged as a powerful tool for ex vivo gene therapy. For the application of ex vivo gene therapy to cardiac diseases, we examined the potential of cell grafting into the intact heart. Of importance, survival of myocyte grafts was observed in the noninfarcted and border-zone areas but not in the infarcted area. Targeted expression of recombinant molecules in intracardiac grafts could induce a beneficial response in the myocardium. Another potential target is the essential transcription factor, NFкB, as NFкB plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes. In vivo transfection of NFкB decoy digodeoxynudeotides (ODN) into the coronary artery before as well as after reperfusion resulted in a marked decrease in the infarcted area. We have reported the first successful gene therapy for myocardial infarction using NFкB decoy ODN. In this chapter, we also discussed the future direction of gene therapy for myocardial infarction.
Key wordscis-Element decoy Hemagglutinating virus of Japan (HVJ)-liposome method Myocardial infarction Transplantation Gene therapy
Unable to display preview. Download preview PDF.
- 7.Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L. Kaneda Y, Ogihara T, Dzau VJ (1993) Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA 90: 8474–8479Google Scholar
- 9.Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ (1995) A novel molecular strategy using cis element “decoy” of E2F binding site inhibits smooth muscle proliferation in vivo. 92: 5855–5859Google Scholar
- 12.Aoki M, Morishita R, Muraishi A, Moriguchi A, Sugimoto T, Maeda K, Dzau VJ, Kaneda Y, Higaki J, Ogihara T (1997) Efficient in vivo gene transfer into heart in rat myocardial infarction model using HVJ (hemagglutinating virus of Japan)-liposome method. J Mol Cell Cardiol 29: 949–959PubMedCrossRefGoogle Scholar
- 17.Aoki M, Morishita R, Higaki J, Moriguchi A, Hayashi S, Matsushita H, Kida I, Tornita N, Sawa Y, Kaneda Y, Ogihara T (1997) Survival of grafts of genetically modified cardiac myocytes transfected with FITC-labeled oligodeoxynucleotides and ß-galactosidase gene in non-infarcted area, but not myocardial infarcted area. Gene Ther 4: 120–127PubMedCrossRefGoogle Scholar
- 20.Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, Kadoba K, Matsuda H (1997) A novel strategy for myocardial protection using in vivo transfection of cis element “decoy” against NFiB binding site: evidence for a role of NFiB in ischemic-reperfusion injury. Circulation 96: II-280-II-285Google Scholar